GlassScriptPhysician profile
Srini B Reddy
NPI 1972627446
$11,253.44
in general payments reported to CMS, 2019-2025
35 companies · $171 in 2025
The $171 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $321 · 2020: $5,081 · 2021: $66.80 · 2022: $1,463 · 2023: $2,670 · 2024: $1,481 · 2025: $171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,600 · Travel and Lodging: $721 · Food and Beverage: $601 · Honoraria: $375 · Education: $25.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,600.00 |
| Travel and Lodging | $720.80 |
| Food and Beverage | $600.60 |
| Honoraria | $375.00 |
| Education | $25.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $4,050.00 | 2020 | |
| Glaxosmithkline, LLC. | $2,618.85 | 2020-2024 | Jemperli |
| G1 Therapeutics, INC. | $1,229.80 | 2023 | Cosela |
| Daiichi Sankyo INC. | $1,054.53 | 2022 | |
| Puma Biotechnology, INC. | $1,015.30 | 2020-2024 | |
| Karyopharm Therapeutics INC. | $157.13 | 2022-2023 | Xpovio |
| Astrazeneca Pharmaceuticals LP | $107.30 | 2019-2024 | Lynparza, Enhertu, Imfinzi |
| Abbvie INC. | $97.63 | 2019-2025 | |
| Intuitive Surgical, INC. | $96.58 | 2022 | |
| Abbott Laboratories | $95.17 | 2022-2024 | Proclaim |
| Pfizer INC. | $81.44 | 2019-2025 | |
| Novocure INC. | $76.01 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $75.34 | 2019 | |
| Exelixis INC. | $65.30 | 2019-2025 | Cabometyx |
| Bayer Healthcare Pharmaceuticals INC. | $48.48 | 2019-2023 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myovant Sciences INC. | $40.76 | 2021 | |
| Medtronic, INC. | $36.01 | 2022-2024 | Osteocool Rf Ablation System |
| Gilead Sciences, INC. | $33.84 | 2021-2025 | Trodelvy |
| Jazz Pharmaceuticals INC. | $27.85 | 2019-2021 | |
| Blueprint Medicines Corporation | $24.76 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.60 | 2023 | Exkivity |
| Mirati Therapeutics, INC. | $23.85 | 2024 | Krazati |
| Adc Therapeutics America, INC. | $23.41 | 2022 | |
| Genzyme Corporation | $17.80 | 2022 | |
| Cti Biopharma Corp. | $17.44 | 2022 | |
| Tactile Systems Technology INC | $17.43 | 2022 | |
| Immunogen, INC. | $17.38 | 2023 | Elahere |
| Astellas Pharma US INC | $16.09 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $14.83 | 2022 | |
| Kite Pharma, INC. | $13.67 | 2019 | |
| Incyte Corporation | $13.32 | 2019 | |
| Tesaro, INC. | $11.36 | 2019 | |
| Clovis Oncology, INC. | $10.18 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Srini Reddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.